PRESS RELEASE

Munich, 6 March 2020

honert have comprehensively advised NeraCare GmbH on the contribution of the shares in Synvie GmbH to NeraCare as well as on the subsequent entry of various MIG-Funds and the BayBG Bayerische Beteiligungsgesellschaft within a series A financing round amounting to a high seven-figure sum.
The NeraCare GmbH has a unique position in the field of precision medicine for the treatment of malignant melanoma (black skin cancer). Within this sector, NeraCare develops and distributes under the brand MelaGenix® a gene expression test to detect and classify any risk of disease recurrence. This test enables the treating physician to assess the risk of disease recurrence of a patient with a high degree of accuracy and to make a substantiated therapy decision based on this information, thus sparing non-endangered patients unnecessary drug therapy.

Consultants of NeraCare GmbH:

honert (Munich): Sven Fritsche; Kai-Klemens Wehlage (both Venture Capital); Susanne Labus (Tax)

Consultants of MIG/BayBG:

Lutz│Abel (Munich): Dr. Bernhard Noreisch (responsible); Jan Phillip Kunz (Venture Capital)